Pro Medicus Limited (PME.AX) Stock Competitors & Peer Comparison
See (PME.AX) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Healthcare Information Services Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| PME.AX | A$188.88 | +1.88% | 19.7B | 83.83 | A$2.25 | +0.33% |
| AYA.AX | A$5.21 | -1.33% | 592.9M | -29.50 | -A$0.18 | N/A |
| CGS.AX | A$2.76 | -0.72% | 468.9M | 29.06 | A$0.09 | +0.72% |
| VHT.AX | A$1.15 | +0.44% | 291.3M | -28.63 | -A$0.04 | N/A |
| ALC.AX | A$0.10 | +1.05% | 129M | 282.35 | A$0.00 | N/A |
| ONE.AX | A$0.14 | -9.68% | 123.2M | -6.52 | -A$0.02 | N/A |
| M7T.AX | A$0.30 | -1.67% | 69.3M | -7.00 | -A$0.04 | N/A |
| SHG.AX | A$0.18 | +2.86% | 57M | -9.00 | -A$0.02 | N/A |
| DOC.AX | A$0.13 | +4.17% | 45.8M | -5.20 | -A$0.02 | N/A |
| BMT.AX | A$0.16 | +10.71% | 45.1M | -7.34 | -A$0.02 | N/A |
Stock Comparison
PME.AX vs AYA.AX Comparison July 2026
PME.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PME.AX stands at 19.7B. In comparison, AYA.AX has a market cap of 592.9M. Regarding current trading prices, PME.AX is priced at A$188.88, while AYA.AX trades at A$5.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PME.AX currently has a P/E ratio of 83.83, whereas AYA.AX's P/E ratio is -29.50. In terms of profitability, PME.AX's ROE is +0.73%, compared to AYA.AX's ROE of -0.36%. Regarding short-term risk, PME.AX is less volatile compared to AYA.AX. This indicates potentially lower risk in terms of short-term price fluctuations for PME.AX.Check AYA.AX's competition here
PME.AX vs CGS.AX Comparison July 2026
PME.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PME.AX stands at 19.7B. In comparison, CGS.AX has a market cap of 468.9M. Regarding current trading prices, PME.AX is priced at A$188.88, while CGS.AX trades at A$2.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PME.AX currently has a P/E ratio of 83.83, whereas CGS.AX's P/E ratio is 29.06. In terms of profitability, PME.AX's ROE is +0.73%, compared to CGS.AX's ROE of +0.22%. Regarding short-term risk, PME.AX is more volatile compared to CGS.AX. This indicates potentially higher risk in terms of short-term price fluctuations for PME.AX.Check CGS.AX's competition here
PME.AX vs VHT.AX Comparison July 2026
PME.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PME.AX stands at 19.7B. In comparison, VHT.AX has a market cap of 291.3M. Regarding current trading prices, PME.AX is priced at A$188.88, while VHT.AX trades at A$1.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PME.AX currently has a P/E ratio of 83.83, whereas VHT.AX's P/E ratio is -28.63. In terms of profitability, PME.AX's ROE is +0.73%, compared to VHT.AX's ROE of -0.18%. Regarding short-term risk, PME.AX is more volatile compared to VHT.AX. This indicates potentially higher risk in terms of short-term price fluctuations for PME.AX.Check VHT.AX's competition here
PME.AX vs ALC.AX Comparison July 2026
PME.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PME.AX stands at 19.7B. In comparison, ALC.AX has a market cap of 129M. Regarding current trading prices, PME.AX is priced at A$188.88, while ALC.AX trades at A$0.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PME.AX currently has a P/E ratio of 83.83, whereas ALC.AX's P/E ratio is 282.35. In terms of profitability, PME.AX's ROE is +0.73%, compared to ALC.AX's ROE of +0.04%. Regarding short-term risk, PME.AX is less volatile compared to ALC.AX. This indicates potentially lower risk in terms of short-term price fluctuations for PME.AX.Check ALC.AX's competition here
PME.AX vs ONE.AX Comparison July 2026
PME.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PME.AX stands at 19.7B. In comparison, ONE.AX has a market cap of 123.2M. Regarding current trading prices, PME.AX is priced at A$188.88, while ONE.AX trades at A$0.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PME.AX currently has a P/E ratio of 83.83, whereas ONE.AX's P/E ratio is -6.52. In terms of profitability, PME.AX's ROE is +0.73%, compared to ONE.AX's ROE of -2.27%. Regarding short-term risk, PME.AX is less volatile compared to ONE.AX. This indicates potentially lower risk in terms of short-term price fluctuations for PME.AX.Check ONE.AX's competition here
PME.AX vs M7T.AX Comparison July 2026
PME.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PME.AX stands at 19.7B. In comparison, M7T.AX has a market cap of 69.3M. Regarding current trading prices, PME.AX is priced at A$188.88, while M7T.AX trades at A$0.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PME.AX currently has a P/E ratio of 83.83, whereas M7T.AX's P/E ratio is -7.00. In terms of profitability, PME.AX's ROE is +0.73%, compared to M7T.AX's ROE of -0.24%. Regarding short-term risk, PME.AX is more volatile compared to M7T.AX. This indicates potentially higher risk in terms of short-term price fluctuations for PME.AX.Check M7T.AX's competition here
PME.AX vs SHG.AX Comparison July 2026
PME.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PME.AX stands at 19.7B. In comparison, SHG.AX has a market cap of 57M. Regarding current trading prices, PME.AX is priced at A$188.88, while SHG.AX trades at A$0.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PME.AX currently has a P/E ratio of 83.83, whereas SHG.AX's P/E ratio is -9.00. In terms of profitability, PME.AX's ROE is +0.73%, compared to SHG.AX's ROE of -0.60%. Regarding short-term risk, PME.AX is less volatile compared to SHG.AX. This indicates potentially lower risk in terms of short-term price fluctuations for PME.AX.Check SHG.AX's competition here
PME.AX vs DOC.AX Comparison July 2026
PME.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PME.AX stands at 19.7B. In comparison, DOC.AX has a market cap of 45.8M. Regarding current trading prices, PME.AX is priced at A$188.88, while DOC.AX trades at A$0.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PME.AX currently has a P/E ratio of 83.83, whereas DOC.AX's P/E ratio is -5.20. In terms of profitability, PME.AX's ROE is +0.73%, compared to DOC.AX's ROE of +2.51%. Regarding short-term risk, PME.AX is more volatile compared to DOC.AX. This indicates potentially higher risk in terms of short-term price fluctuations for PME.AX.Check DOC.AX's competition here
PME.AX vs BMT.AX Comparison July 2026
PME.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PME.AX stands at 19.7B. In comparison, BMT.AX has a market cap of 45.1M. Regarding current trading prices, PME.AX is priced at A$188.88, while BMT.AX trades at A$0.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PME.AX currently has a P/E ratio of 83.83, whereas BMT.AX's P/E ratio is -7.34. In terms of profitability, PME.AX's ROE is +0.73%, compared to BMT.AX's ROE of -0.14%. Regarding short-term risk, PME.AX is more volatile compared to BMT.AX. This indicates potentially higher risk in terms of short-term price fluctuations for PME.AX.Check BMT.AX's competition here
PME.AX vs COO.AX Comparison July 2026
PME.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PME.AX stands at 19.7B. In comparison, COO.AX has a market cap of 26.3M. Regarding current trading prices, PME.AX is priced at A$188.88, while COO.AX trades at A$0.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PME.AX currently has a P/E ratio of 83.83, whereas COO.AX's P/E ratio is N/A. In terms of profitability, PME.AX's ROE is +0.73%, compared to COO.AX's ROE of -0.05%. Regarding short-term risk, PME.AX is more volatile compared to COO.AX. This indicates potentially higher risk in terms of short-term price fluctuations for PME.AX.Check COO.AX's competition here
PME.AX vs PKY.AX Comparison July 2026
PME.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PME.AX stands at 19.7B. In comparison, PKY.AX has a market cap of 25.2M. Regarding current trading prices, PME.AX is priced at A$188.88, while PKY.AX trades at A$0.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PME.AX currently has a P/E ratio of 83.83, whereas PKY.AX's P/E ratio is -11.27. In terms of profitability, PME.AX's ROE is +0.73%, compared to PKY.AX's ROE of -11.22%. Regarding short-term risk, PME.AX is less volatile compared to PKY.AX. This indicates potentially lower risk in terms of short-term price fluctuations for PME.AX.Check PKY.AX's competition here
PME.AX vs TRI.AX Comparison July 2026
PME.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PME.AX stands at 19.7B. In comparison, TRI.AX has a market cap of 24.2M. Regarding current trading prices, PME.AX is priced at A$188.88, while TRI.AX trades at A$0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PME.AX currently has a P/E ratio of 83.83, whereas TRI.AX's P/E ratio is N/A. In terms of profitability, PME.AX's ROE is +0.73%, compared to TRI.AX's ROE of -0.08%. Regarding short-term risk, PME.AX is less volatile compared to TRI.AX. This indicates potentially lower risk in terms of short-term price fluctuations for PME.AX.Check TRI.AX's competition here
PME.AX vs RHT.AX Comparison July 2026
PME.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PME.AX stands at 19.7B. In comparison, RHT.AX has a market cap of 21.9M. Regarding current trading prices, PME.AX is priced at A$188.88, while RHT.AX trades at A$0.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PME.AX currently has a P/E ratio of 83.83, whereas RHT.AX's P/E ratio is 28.93. In terms of profitability, PME.AX's ROE is +0.73%, compared to RHT.AX's ROE of +0.08%. Regarding short-term risk, PME.AX is more volatile compared to RHT.AX. This indicates potentially higher risk in terms of short-term price fluctuations for PME.AX.Check RHT.AX's competition here
PME.AX vs EMD.AX Comparison July 2026
PME.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PME.AX stands at 19.7B. In comparison, EMD.AX has a market cap of 21.2M. Regarding current trading prices, PME.AX is priced at A$188.88, while EMD.AX trades at A$0.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PME.AX currently has a P/E ratio of 83.83, whereas EMD.AX's P/E ratio is -4.58. In terms of profitability, PME.AX's ROE is +0.73%, compared to EMD.AX's ROE of -0.52%. Regarding short-term risk, PME.AX is more volatile compared to EMD.AX. This indicates potentially higher risk in terms of short-term price fluctuations for PME.AX.Check EMD.AX's competition here
PME.AX vs PCK.AX Comparison July 2026
PME.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PME.AX stands at 19.7B. In comparison, PCK.AX has a market cap of 20.9M. Regarding current trading prices, PME.AX is priced at A$188.88, while PCK.AX trades at A$0.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PME.AX currently has a P/E ratio of 83.83, whereas PCK.AX's P/E ratio is -4.00. In terms of profitability, PME.AX's ROE is +0.73%, compared to PCK.AX's ROE of -10.10%. Regarding short-term risk, PME.AX is less volatile compared to PCK.AX. This indicates potentially lower risk in terms of short-term price fluctuations for PME.AX.Check PCK.AX's competition here
PME.AX vs VHL.AX Comparison July 2026
PME.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PME.AX stands at 19.7B. In comparison, VHL.AX has a market cap of 18.4M. Regarding current trading prices, PME.AX is priced at A$188.88, while VHL.AX trades at A$0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PME.AX currently has a P/E ratio of 83.83, whereas VHL.AX's P/E ratio is -0.82. In terms of profitability, PME.AX's ROE is +0.73%, compared to VHL.AX's ROE of -4.12%. Regarding short-term risk, PME.AX is less volatile compared to VHL.AX. This indicates potentially lower risk in terms of short-term price fluctuations for PME.AX.Check VHL.AX's competition here
PME.AX vs IME.AX Comparison July 2026
PME.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PME.AX stands at 19.7B. In comparison, IME.AX has a market cap of 16.6M. Regarding current trading prices, PME.AX is priced at A$188.88, while IME.AX trades at A$0.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PME.AX currently has a P/E ratio of 83.83, whereas IME.AX's P/E ratio is -3.97. In terms of profitability, PME.AX's ROE is +0.73%, compared to IME.AX's ROE of -0.19%. Regarding short-term risk, PME.AX is more volatile compared to IME.AX. This indicates potentially higher risk in terms of short-term price fluctuations for PME.AX.Check IME.AX's competition here
PME.AX vs 1ST.AX Comparison July 2026
PME.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PME.AX stands at 19.7B. In comparison, 1ST.AX has a market cap of 15.6M. Regarding current trading prices, PME.AX is priced at A$188.88, while 1ST.AX trades at A$0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PME.AX currently has a P/E ratio of 83.83, whereas 1ST.AX's P/E ratio is -1.10. In terms of profitability, PME.AX's ROE is +0.73%, compared to 1ST.AX's ROE of +0.69%. Regarding short-term risk, PME.AX is more volatile compared to 1ST.AX. This indicates potentially higher risk in terms of short-term price fluctuations for PME.AX.Check 1ST.AX's competition here
PME.AX vs MDR.AX Comparison July 2026
PME.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PME.AX stands at 19.7B. In comparison, MDR.AX has a market cap of 14M. Regarding current trading prices, PME.AX is priced at A$188.88, while MDR.AX trades at A$0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PME.AX currently has a P/E ratio of 83.83, whereas MDR.AX's P/E ratio is -0.20. In terms of profitability, PME.AX's ROE is +0.73%, compared to MDR.AX's ROE of -2.31%. Regarding short-term risk, PME.AX is less volatile compared to MDR.AX. This indicates potentially lower risk in terms of short-term price fluctuations for PME.AX.Check MDR.AX's competition here
PME.AX vs ICR.AX Comparison July 2026
PME.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PME.AX stands at 19.7B. In comparison, ICR.AX has a market cap of 10.4M. Regarding current trading prices, PME.AX is priced at A$188.88, while ICR.AX trades at A$0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PME.AX currently has a P/E ratio of 83.83, whereas ICR.AX's P/E ratio is -4.06. In terms of profitability, PME.AX's ROE is +0.73%, compared to ICR.AX's ROE of +5.38%. Regarding short-term risk, PME.AX is more volatile compared to ICR.AX. This indicates potentially higher risk in terms of short-term price fluctuations for PME.AX.Check ICR.AX's competition here
PME.AX vs OPL.AX Comparison July 2026
PME.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PME.AX stands at 19.7B. In comparison, OPL.AX has a market cap of 5.4M. Regarding current trading prices, PME.AX is priced at A$188.88, while OPL.AX trades at A$0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PME.AX currently has a P/E ratio of 83.83, whereas OPL.AX's P/E ratio is -2.20. In terms of profitability, PME.AX's ROE is +0.73%, compared to OPL.AX's ROE of +12.68%. Regarding short-term risk, PME.AX is more volatile compared to OPL.AX. This indicates potentially higher risk in terms of short-term price fluctuations for PME.AX.Check OPL.AX's competition here
PME.AX vs VFX.AX Comparison July 2026
PME.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PME.AX stands at 19.7B. In comparison, VFX.AX has a market cap of 5.2M. Regarding current trading prices, PME.AX is priced at A$188.88, while VFX.AX trades at A$0.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PME.AX currently has a P/E ratio of 83.83, whereas VFX.AX's P/E ratio is -3.00. In terms of profitability, PME.AX's ROE is +0.73%, compared to VFX.AX's ROE of +2.45%. Regarding short-term risk, PME.AX is less volatile compared to VFX.AX. This indicates potentially lower risk in terms of short-term price fluctuations for PME.AX.Check VFX.AX's competition here
PME.AX vs MEB.AX Comparison July 2026
PME.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PME.AX stands at 19.7B. In comparison, MEB.AX has a market cap of 4.5M. Regarding current trading prices, PME.AX is priced at A$188.88, while MEB.AX trades at A$0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PME.AX currently has a P/E ratio of 83.83, whereas MEB.AX's P/E ratio is -0.10. In terms of profitability, PME.AX's ROE is +0.73%, compared to MEB.AX's ROE of -0.15%. Regarding short-term risk, PME.AX is less volatile compared to MEB.AX. This indicates potentially lower risk in terms of short-term price fluctuations for PME.AX.Check MEB.AX's competition here
PME.AX vs ENL.AX Comparison July 2026
PME.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PME.AX stands at 19.7B. In comparison, ENL.AX has a market cap of 4.2M. Regarding current trading prices, PME.AX is priced at A$188.88, while ENL.AX trades at A$0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PME.AX currently has a P/E ratio of 83.83, whereas ENL.AX's P/E ratio is -0.17. In terms of profitability, PME.AX's ROE is +0.73%, compared to ENL.AX's ROE of -1.39%. Regarding short-term risk, PME.AX is more volatile compared to ENL.AX. This indicates potentially higher risk in terms of short-term price fluctuations for PME.AX.Check ENL.AX's competition here
PME.AX vs HIQ.AX Comparison July 2026
PME.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PME.AX stands at 19.7B. In comparison, HIQ.AX has a market cap of 4M. Regarding current trading prices, PME.AX is priced at A$188.88, while HIQ.AX trades at A$0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PME.AX currently has a P/E ratio of 83.83, whereas HIQ.AX's P/E ratio is -0.59. In terms of profitability, PME.AX's ROE is +0.73%, compared to HIQ.AX's ROE of +1.53%. Regarding short-term risk, PME.AX is less volatile compared to HIQ.AX. This indicates potentially lower risk in terms of short-term price fluctuations for PME.AX.Check HIQ.AX's competition here
PME.AX vs TD1.AX Comparison July 2026
PME.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PME.AX stands at 19.7B. In comparison, TD1.AX has a market cap of 3.7M. Regarding current trading prices, PME.AX is priced at A$188.88, while TD1.AX trades at A$0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PME.AX currently has a P/E ratio of 83.83, whereas TD1.AX's P/E ratio is -3.27. In terms of profitability, PME.AX's ROE is +0.73%, compared to TD1.AX's ROE of -0.42%. Regarding short-term risk, PME.AX is more volatile compared to TD1.AX. This indicates potentially higher risk in terms of short-term price fluctuations for PME.AX.Check TD1.AX's competition here
PME.AX vs OAK.AX Comparison July 2026
PME.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PME.AX stands at 19.7B. In comparison, OAK.AX has a market cap of 2.1M. Regarding current trading prices, PME.AX is priced at A$188.88, while OAK.AX trades at A$0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PME.AX currently has a P/E ratio of 83.83, whereas OAK.AX's P/E ratio is N/A. In terms of profitability, PME.AX's ROE is +0.73%, compared to OAK.AX's ROE of +0.17%. Regarding short-term risk, PME.AX is more volatile compared to OAK.AX. This indicates potentially higher risk in terms of short-term price fluctuations for PME.AX.Check OAK.AX's competition here
PME.AX vs JTL.AX Comparison July 2026
PME.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PME.AX stands at 19.7B. In comparison, JTL.AX has a market cap of 281.3K. Regarding current trading prices, PME.AX is priced at A$188.88, while JTL.AX trades at A$0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PME.AX currently has a P/E ratio of 83.83, whereas JTL.AX's P/E ratio is -0.10. In terms of profitability, PME.AX's ROE is +0.73%, compared to JTL.AX's ROE of +0.60%. Regarding short-term risk, PME.AX is more volatile compared to JTL.AX. This indicates potentially higher risk in terms of short-term price fluctuations for PME.AX.Check JTL.AX's competition here
PME.AX vs TTB.AX Comparison July 2026
PME.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PME.AX stands at 19.7B. In comparison, TTB.AX has a market cap of 267.4K. Regarding current trading prices, PME.AX is priced at A$188.88, while TTB.AX trades at A$0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PME.AX currently has a P/E ratio of 83.83, whereas TTB.AX's P/E ratio is -0.02. In terms of profitability, PME.AX's ROE is +0.73%, compared to TTB.AX's ROE of -1.05%. Regarding short-term risk, PME.AX is more volatile compared to TTB.AX. This indicates potentially higher risk in terms of short-term price fluctuations for PME.AX.Check TTB.AX's competition here